Over 80 Respiratory Medicine Specialists from Across Korea Attend to Share the Latest Insights in ILD

ILDONG Pharmaceutical (CEO Woongsup Yun) announced on the 28th Apr, 2025 that it successfully held a launch symposium for its interstitial lung disease (ILD) treatment, Cuninta Tab. (ingredient: Nintedanib).

The event was held on 26–27  April 2025 at the Gravity Josun Seoul Pangyo hotel in Seongnam, Gyeonggi Province, and was attended by more than 80 respiratory medicine specialists from across the country. Notably, Professor Dong Soon Kim, Professor at the University of Ulsan College of Medicine and a recognized expert in the ILD field both domestically and internationally, also participated and added prestige to the event.

In his congratulatory remarks, Professor Kim stated, “In the past, due to a lack of research data, treatment options, and clinical experience regarding ILD, many unfortunate situations occurred in clinical practice. However, since the 2010s, thanks to the efforts of medical professionals and pharmaceutical companies, the path for patient treatment has broadened. I hope to see continued interest in the research, development, and distribution of therapies in the ILD field.”

The symposium focused on sharing the latest knowledge on the treatment of interstitial lung diseases, such as progressive pulmonary fibrosis (PPF), for which Nintedanib is expected to be covered by national health insurance.

Progressive pulmonary fibrosis (PPF) refers to a group of non-idiopathic pulmonary fibrosis (non-IPF ILDs) that show rapid progression of lung fibrosis despite appropriate treatment. PPF is known to have a poor prognosis, making early detection and proactive treatment crucial.

The special lecture session consisted of four topics related to ILD and its treatments. Professor Man Pyo Jung of Samsung Medical Center served as the chair, and speakers included Professor Yang Jin Jegal of Ulsan University Hospital, Professor Ju Hun Park of Ajou University Hospital, Professor Hyun Kyung Lee of Busan Paik Hospital, and Professor Jin Woo Song of Asan Medical Center in Seoul.

Professor Hyun Kyung Lee, who presented on “Managing Adverse Effects of Nintedanib and Patient Treatment Strategies,” emphasized that “Although Nintedanib is currently recommended for use in PPF, managing side effects from the patient's perspective is also essential.”

She added, “Cuninta is in tablet form, which reduces the risk of residue in the oral mucosa, and the small pill size allows for quicker passage through the esophagus.” She also noted, “It is impressive that the product is packaged in PTP aluminum blister packs that block heat and moisture, demonstrating thoughtful consideration for patient convenience.”

ILDONG Pharmaceutical plans to leverage its long-standing academic network and marketing capabilities in the pulmonary disease field, along with its newly launched respiratory product lineup including Cuninta, to actively expand its market presence. The company also reaffirmed its commitment to improving patient treatment outcomes and quality of life.